Regenxbio's main product, RGX-314, for wet AMD has a large potential market but with many competitors.
RGX-314 is competitive with current treatments with a mix of pros and cons.
Even though I am not entirely sold on the blockbuster potential of RGX-314, valuation wise, it is fairly valued. There is a potential upside with the pipeline and NAV technology platform.
Regenxbio (RGNX) is a clinical-stage biotechnology focusing on gene therapy. Gene therapy products are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce